4D Molecular Therapeutics Dividend

Dividend criteria checks 0/6

4D Molecular Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.9%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$1.97
Dividend yield forecast in 3Y	0%

Recent dividend updates

No updates

Recent updates

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

Apr 29

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

Feb 06

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Jan 25

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 12

We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Nov 08

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

May 08

We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Sep 29

4D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M

Aug 11

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

Jun 11

We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely

Aug 06

Newsflash: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Analysts Have Been Trimming Their Revenue Forecasts

Jun 28

4D Molecular inks collaboration deal on machine learning technology

May 04

We Think 4D Molecular Therapeutics (NASDAQ:FDMT) Can Afford To Drive Business Growth

May 04

Have Insiders Been Buying 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares?

Mar 11

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if FDMT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FDMT's dividend payments have been increasing.

Dividend Yield vs Market

4D Molecular Therapeutics Dividend Yield vs Market

How does FDMT dividend yield compare to the market?
Segment	Dividend Yield
Company (FDMT)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Biotechs)	2.9%
Analyst forecast in 3 Years (FDMT)	0%

Notable Dividend: Unable to evaluate FDMT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FDMT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate FDMT's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as FDMT has not reported any payouts.

4D Molecular Therapeutics Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

New major risk - Shareholder dilution

4D Molecular Therapeutics, Inc., Annual General Meeting, May 21, 2024

Insider notifies of intention to sell stock

New major risk - Revenue and earnings growth

Price target increased by 9.3% to US$54.75

4Dmt Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

Consensus revenue estimates decrease by 33%, EPS upgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

4D Molecular Therapeutics, Inc. Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024

Chief Medical Officer exercised options and sold US$354k worth of stock

New major risk - Shareholder dilution

4D Molecular Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $299.999626 million.

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

4D Molecular Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

New major risk - Share price stability

Price target increased by 9.6% to US$37.00

4D Molecular Therapeutics Presents Positive Interim Data from Randomized Phase 2 Prism Clinical Trial of Intravitreal 4D-150

Co-Founder notifies of intention to sell stock

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Co-Founder notifies of intention to sell stock

4D Molecular Therapeutics Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates

4D Molecular Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD

Co-Founder notifies of intention to sell stock

Insufficient new directors

Consensus revenue estimates increase by 96%

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

4D Molecular Therapeutics Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis At 2023 NACFC

4D Molecular Therapeutics, Inc. Announced Alignment with the U.S. Food and Drug Administration on A Plan to Lift the Clinical Hold on the Phase 1/2 Inglaxa Clinical Trial in the United States

4D Molecular Therapeutics, Inc. Announces Executive Changes

Price target decreased by 14% to US$33.50

4D Molecular Therapeutics, Inc. Announces First Patient Enrolled in 4D-150 Phase 2 Spectra Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in Prism Clinical Trial in Wet AMD

Consensus revenue estimates increase by 41%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 Prism Clinical Trial in Patients with Wet AMD at ASRS 2023

Consensus revenue estimates increase by 163%

4D Molecular Therapeutics Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at ECFS 46th Annual Meeting

4Dmt to Present Interim Data from 4D-710 Phase 1/2 Aerow Clinical Trial for Cystic Fibrosis Lung Disease At the European Cystic Fibrosis Society (Ecfs) 46Th Annual Meeting

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

Price target increased by 8.3% to US$41.17

Full year 2022 earnings: EPS and revenues miss analyst expectations

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema

Price target increased by 8.1% to US$38.00

4D Molecular Therapeutics, Inc. Announces Updates on Clinical Pipeline and Additional Preclinical Programs

4D Molecular Therapeutics, Inc. Announces Updates on Clinical Pipeline and Additional Preclinical Programs

Co-Founder notifies of intention to sell stock

Insider exercised options and sold US$85k worth of stock

Price target increased to US$23.80

High number of new directors

4D Molecular Therapeutics, Inc. Announces Interim Clinical Data from On-Going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration

4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released November 14, 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

4D Molecular Therapeutics, Inc. Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease At NACFC 2022

High number of new directors

High number of new directors

We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

4D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M

4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) dropped from Russell 2000 Growth Index

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

Price target decreased to US$21.00

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$32.00

4D Molecular Therapeutics, Inc., Annual General Meeting, May 23, 2022

4D Molecular Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-710

Consensus revenue estimates fall by 11%

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

4D Molecular Therapeutics, Inc. Announces Resignation of David Schaffer from Its Board of Directors and His Roles on the Nominating and Corporate Governance Committee and Science & Technology Committee

4D Molecular Therapeutics, Inc. Announces Update on Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease at the 18th Annual WORLDSymposium

4D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for the Treatment of X-linked Retinitis Pigmentosa

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-150, A Dual-Transgene Intravitreal Gene Therapy for Patients with Wet AMD